Search

Displaying results 3151 - 3160 of 5506 in total
  1. Drug

    C11-12 isoparaffin

    go.drugbank.com/drugs/DB11329
    Approved

    It is found in cosmetic and personal care products as solvents or skin conditioning agent.

  2. Drug

    Zirconium panitumumab Zr-89

    go.drugbank.com/drugs/DB19228
    Investigational

    Zirconium panitumumab Zr-89 is under investigation in clinical trial NCT05423197 (Study Evaluating Zr-panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous

  3. Drug

    Sargramostim

    go.drugbank.com/drugs/DB00020
    ApprovedInvestigational

    It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.

  4. Drug

    Stearic acid

    go.drugbank.com/drugs/DB03193
    Approved

    It is a waxy solid.

    Mixtures: Huile D'onagre Vitamin E
  5. Drug

    BI-K0376

    go.drugbank.com/drugs/DB05858
    Experimental

    It is under investigation by Pfizer and has gone through phase I of the clinical trails.

  6. Drug

    Adenine

    go.drugbank.com/drugs/DB00173
    ApprovedInvestigationalNutraceutical

    A purine base and a fundamental unit of adenine nucleotides.

  7. Drug

    Adrafinil

    go.drugbank.com/drugs/DB08925
    ApprovedWithdrawn

    It was marketed in France and elsewhere in Europe under the trade name Olmifon until September 2011 when France's FDA equivalent reassessed the drug and withdrew marketing permission. … It is also been used off-label to prevent fatigue or falling asleep for extended periods of time. Adrafinil does not currently have FDA approval and is thus unregulated in the United States.

  8. Drug

    Lymecycline

    go.drugbank.com/drugs/DB00256
    ApprovedInvestigationalWithdrawn

    It is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries. … [L13880,L13883] It has been proven a cost-effective alternative to treatment with [minocycline] with comparable safety and efficacy.[A203255] Lymecycline was initially discovered in 1961.

  9. Drug

    Relugolix

    go.drugbank.com/drugs/DB11853
    ApprovedInvestigational

    It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids,[A225816] and more recently by the United States' FDA in 2020, under the brand name

  10. Drug

    Enlicitide

    go.drugbank.com/drugs/DB22580
    ApprovedInvestigational

    Across two 52-week placebo-controlled trials, enlicitide 20 mg once daily reduced LDL-C at Week 24 by 56% relative to placebo in patients with hypercholesterolemia at established or increased ASCVD risk … It is formulated as enlicitide decanoate alongside the permeation enhancer sodium caprate, which facilitates absorption of the peptide across the gastrointestinal tract, though oral bioavailability remains